Biomarkers of clinical benefit for anti-epidermal growth factor receptor agents in patients with non-small-cell lung cancer

Por Pallis, A G, Fennell, D A, Szutowicz, E, Leighl, N B, Greillier, L, Dziadziuszko, R
Publicado em 2011

ErbB-3 expression is associated with E-cadherin and their coexpression restores response to gefitinib in non-small-cell lung cancer (NSCLC)

Por Witta, S. E., Dziadziuszko, R., Yoshida, K., Hedman, K., Varella-Garcia, M., Bunn, P. A., Hirsch, F. R.
Publicado em 2009

A prospective, randomised study to compare two palliative radiotherapy schedules for non-small-cell lung cancer (NSCLC)

Por Senkus-Konefka, E, Dziadziuszko, R, Bednaruk-Młyński, E, Pliszka, A, Kubrak, J, Lewandowska, A, Małachowski, K, Wierzchowski, M, Matecka-Nowak, M, Jassem, J
Publicado em 2005

LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective

Por Adebahr, S, Collette, S, Shash, E, Lambrecht, M, Le Pechoux, C, Faivre-Finn, C, De Ruysscher, D, Peulen, H, Belderbos, J, Dziadziuszko, R, Fink, C, Guckenberger, M, Hurkmans, C, Nestle, U
Publicado no Br J Radiol (2015)

Stereotactic body radiotherapy for central lung tumours: Author reply

Por Adebahr, S, Collette, S, Shash, E, Lambrecht, M, Le Pechoux, C, Faivre-Finn, C, De Ruysscher, D, Peulen, H, Belderbos, J, Dziadziuszko, R, Fink, C, Guckenberger, M, Hurkmans, C, Nestle, U
Publicado no Br J Radiol (2015)

Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study

Por Novello, S, Mazières, J, Oh, I -J, de Castro, J, Migliorino, M R, Helland, Å, Dziadziuszko, R, Griesinger, F, Kotb, A, Zeaiter, A, Cardona, A, Balas, B, Johannsdottir, H K, Das-Gupta, A, Wolf, J
Publicado no Ann Oncol (2018)